Inflammation mediates tumor-induced tolerance. The induction and the maintenance of the chronic inflammatory response is a universal mechanism of immune tolerance.
Glatiramer acetate (GA) is approved for the treatment of multiple sclerosis (MS). However, the mechanism of action of GA in MS is still unclear. In particular, it is not known whether GA can modulate the pro-inflammatory Th17-type immune response in MS. We investigated the effects of original GA (Copaxone
®
, Teva, Israel) and generic GA (Timexone
®
, Biocad, Russia) on Th17- and Th1-type cytokine production
in vitro
in 25 patients with relapsing-remitting MS and 25 healthy subjects. Both original and generic GA at concentrations 50–200 μg/ml dose-dependently inhibited interleukin-17 and interferon-γ production by anti-CD3/anti-CD28-activated peripheral blood mononuclear cells from MS patients and healthy subjects. This effect of GA was reproduced using purified CD4
+
T cells, suggesting that GA can directly modulate the functions of Th17 and Th1 cells. At high concentrations (100–200 μg/ml), GA also suppressed the production of Th17-differentiation cytokines (interleukin-1β and interleukin-6) by lipopolysaccharide (LPS)-activated dendritic cells (DCs). These GA/LPS-treated DCs induced lower interleukin-17 and interferon-γ production by autologous CD4
+
T cells compared to LPS-treated DCs. These data suggest that GA can inhibit Th17-immune response and that this inhibitory effect is preferentially exercised by direct influence of GA on T cells. We also demonstrate a comparable ability of original and generic GA to modulate pro-inflammatory cytokine production.
Background:
Prostate cancer is one of the most frequent types of cancer. Despite the existence of various
treatment strategies, treatment of prostate cancer still presents serious difficulties (especially in advanced stages).
Polyphenols have been extensively assessed in terms of their potential use for prostate cancer treatment and prevention.
Catechins are among the most well-known polyphenols in this respect.
Objective:
In this review, we summarize clinical study results concerning catechin applications with regard to prostate
cancer treatment and prevention. We discuss some of the main mechanisms of the anticarcinogenic action of
catechins.
Conclusion:
The main mechanisms of the anticarcinogenic action of catechins are subdivided into two major types:
(i) direct action on cancer cells and (ii) indirect effect based on catechins’s impact on the microenvironment of cancer
cells, particularly in relation to the immune system. At this level catechins might reduce tumor-associated inflammation
and immune tolerance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.